FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events

The U.S. Food and Drug Administration (FDA) today directed the manufacturers
of all drug products approved for the treatment of Attention Deficit Hyperactivity
Disorder (ADHD) to develop Patient Medication Guides to alert patients to possible
cardiovascular risks and risks of adverse psychiatric symptoms associated with
the medicines, and to advise them of precautions that can be taken.